DOCSLIB.ORG

The Cancer Genome Challenge

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Cancer Genome Challenge NEWS FEATURE NATURE|Vol 464|15 April 2010 The ANCER GEN ME challenge Databases could soon be flooded with genome sequences from 25,000 tumours. Heidi Ledford looks at the obstacles researchers face as they search for meaning in the data. hen it was first discovered, in needle pulled from a veritable haystack of 2006, in a study of 35 colorec- GENOMES AT A GLANCE cancer-associated mutations thanks to high- tal cancers1, the mutation in the Circos plots can give a snapshot of the mutations within powered genome sequencing. In the past two gene IDH1 seemed to have little a genome. The outer ring represents the chromosomes years, labs around the world have teamed W and the inner rings each detail the location of different consequence. It appeared in only one of the types of mutations. up to sequence the DNA from thousands of tumours sampled, and later analyses of some tumours along with healthy cells from the same 300 more have revealed no additional muta- individuals. Roughly 75 cancer genomes have tions in the gene. The mutation changed only Interchromosomal been sequenced to some extent and published; rearrangement Point mutation one letter of IDH1, which encodes isocitrate Y researchers expect to have several hundred X dehydrogenase, a lowly housekeeping enzyme 1 completed sequences by the end of the year. 22 involved in metabolism. And there were plenty 21 The efforts are certainly creating bigger hay- 20 of other mutations to study in the 13,000 genes 2 stacks. Comparing the gene sequence of any sequenced from each sample. “Nobody tumour to that of a normal cell reveals dozens 19 would have expected IDH1 to be impor- of single-letter changes, or point mutations, (2009). 719–724 458, tant in cancer,” says Victor Velculescu, a 18 along with repeated, deleted, swapped or researcher at the Sidney Kimmel Com- 3 inverted sequences (see ‘Genomes at prehensive Cancer Center at Johns 17 a glance’). “The difficulty,” says Bert NATURE Hopkins University in Baltimore, Vogelstein, a cancer researcher at the 16 UTREAL F Maryland, who had contributed to Ludwig Center for Cancer Genetics . A . P the study. 4 and Therapeutics at Johns Hopkins, But as efforts to sequence tumour 15 “is going to be figuring out how to DNA expanded, the IDH1 muta- use the information to help people tion surfaced again: in 12% of sam- rather than to just catalogue lots and 14 & CAMPBELL J. ples of a type of brain cancer called lots of mutations”. No matter how P glioblastoma multiforme2, then in 5 similar they might look clinically, 8% of acute myeloid leukaemia sam- 13 most tumours seem to differ geneti- 3 STRATTON, . R ples . Structural studies showed that the cally. This stymies efforts to distinguish . 6 M mutation changed the activity of isocitrate 12 the mutations that cause and accelerate dehydrogenase, causing a cancer-promoting cancers — the drivers — from the accidental metabolite to accumulate in cells4. And at least by-products of a cancer’s growth and thwarted 11 7 one pharmaceutical company — Agios Phar- DNA-repair mechanisms — the passengers. 8 FROM ADAPTED 10 maceuticals in Cambridge, Massachusetts — is 9 Researchers can look for mutations that pop up already hunting for a drug to stop the process. again and again, or they can identify key path- Four years after the initial discovery, ask Intrachromosomal ways that are mutated at different points. But rearrangement a researcher in the field why cancer genome Copy-number change the projects are providing more questions than projects are worthwhile, and many will probably answers. “Once you take the few obvious muta- bring up the IDH1 mutation, the inconspicuous tions at the top of the list, how do you make 972 © 2010 Macmillan Publishers Limited. All rights reserved VolNATURE 464|15|Vol April 464 2010|15 April 2010 NEWS FEATURE Canada Britain • Pancreatic cancer • Breast cancer 1 (ductal adenocarcinoma) (ER–, PR–, HER–) Germany • Breast cancer (lobular) • Paediatric brain tumours 3 • Breast cancer (ER+, HER–) (medulloblastoma, – European Union sponsored pilocytic astrocytoma) 1 1 China 1 • Gastric cancer United States Spain 6+ – Through the Cancer Genome Atlas • Chronic 1 • Ovarian cancer lymphocytic • Brain cancer leukaemia 3 1 (glioblastoma multiforme) India • Lung cancer • Oral cancer (squamous-cell carcinoma) France (gingivobuccal) 1 Japan • Lung cancer • Breast cancer • Liver cancer (adenocarcinoma) (HER2 overexpressing) (virus-associated) • Acute myeloid leukaemia • Liver cancer Italy • Colon cancer (alcohol-associated) • Rare pancreatic cancers (adenocarcinoma) • Renal-cell carcinoma (enteropancreatic endocrine, • Others – European Union sponsored pancreatic exocrine) ALL TOGETHER NOW Number of Australia Eleven countries have signed on to sequence DNA from 500 tumour samples for cancer types • Pancreatic cancer each of more than 20 cancer types for the International Cancer Genome Consortium. 1 being sequenced 2 (ductal adenocarcinoma) Each cancer type is estimated to cost nearly US$20 million to sequence. • Ovarian cancer sense of the rest of them?” asks Will Parsons, a useful, says Joe Gray, a cancer researcher at 1% of the cancers,” says Vogelstein. To find these paediatric oncologist at Baylor College of Medi- Lawrence Berkeley National Laboratory in low-frequency drivers, researchers are sampling cine in Houston, Texas. “How do you decide California, but it’s just a start. “In the early days, heavily — sequencing 500 samples per cancer which are worthy of follow up and functional I thought that doing a few hundred tumours should reveal mutations that are present in as analysis? That’s going to be the hard part.” would probably be sufficient,” he says. “Even at few as 3% of the tumours. Although they may the level of 1,000 samples, I think we’re probably not contribute to the majority of tumours, they Drivers wanted not going to have the statistics we want.” may still have important biological lessons, Because cancer is a disease so intimately What bigger numbers could provide is more says Stratton. “We need to know about these associated with genetic mutation, many thought driver mutations like the one in IDH1. These to understand the overall genomic landscape it would be amenable to genomic exploration could, researchers argue, provide the clear- of cancer.” through initiatives based on the collaborative est route to developing new cancer therapies. Another popular approach has been to model of the Human Genome Project. The Many scientists have looked for mutations that look for mutations that cluster in a pathway, a International Cancer Genome Consortium occur repeatedly in a given type of tumour. “If group of genes that work together to carry out a (ICGC), formed in 2008, is coordinating efforts there are lots and lots of abnor- specific process, even if the to sequence 500 tumours from each of 50 can- malities of a particular gene, the “It’s going to take mutations strike it at different cers. Together, these projects will cost in the most likely explanation is often good old-fashioned points. In an analysis of 24 pan- 6 order of US$1 billion. Eleven countries have that those mutations have been biology to really creatic cancers , for instance, already signed on to cover more than 20 cancers selected for by the cancers and Vogelstein and his colleagues (see map). The ICGC includes two older, large- therefore they are cancer-caus- determine what these identified 12 signalling path- scale projects: the Cancer Genome Project, at ing,” says Michael Stratton, who mutations are doing.” ways that had been altered. the Wellcome Trust Sanger Institute near Cam- co-directs the Cancer Genome Nevertheless, Vogelstein cau- bridge, UK, and the US National Institutes of Project. This approach has worked well in some tions that this approach is not easy to pursue. Health’s Cancer Genome Atlas (TCGA). The cancers. For example, with a frequency of 12%, Many pathways overlap, and their boundaries Cancer Genome Project has churned out more it is clear that the IDH1 mutation is a driver in are unclear. And because many have been than 100 partial genomes and roughly 15 whole glioblastoma. Such searches should be fruitful defined using data from different animals or genomes in various stages of completion, and for cancers that have fewer mutations overall. cell types, they do not always match what’s intends to tackle 2,000–3,000 more over the The full genome sequence of acute myeloid found in a specific human tissue. “When you next 5–7 years. TCGA, meanwhile, wrapped leukaemia cells yielded just ten mutations in layer on top of that the fact that the cancer cell up a three-year, three-cancer pilot project last protein-coding genes, eight of which had not is not wired the same as a normal cell, that raises year, then launched a full-scale endeavour to previously been linked with cancer5. even further difficulties,” says Vogelstein. sequence up to 500 tumours from each of more Other cancers have proved more challeng- than 20 cancers over the next five years. ing. IDH1 was overlooked at first, on the basis How much is enough? Although the groups collaborate, TCGA has of the colorectal cancer data alone. It was not Separating drivers from passengers will not yet been able to fully join the ICGC owing until the search was expanded to other cancers become even more difficult as researchers to differences in privacy regulations govern- that its importance was revealed. Moreover, move towards sequencing entire tumour ing access to genome data. For now, members some mutations shown to be drivers haven’t genomes. To date, only a fraction of the exist- of both consortia are sequencing a subset of turned up as often as expected. “It’s very clear, ing cancer genomes are complete sequences. tumour samples from each cancer type — now that all the genes have been sequenced in To keep costs low, most have covered only the around 100 — and will follow this by sequencing this many tumours, you have drivers that are exome, the 1.5% of the genome that directly promising areas in the remaining 400.
Load more

Recommended publications
  • Insights Into the Genetic Basis of the Renal Cell Carcinomas from the Cancer Genome Atlas Scott M
    Published OnlineFirst June 21, 2016; DOI: 10.1158/1541-7786.MCR-16-0115 Review Molecular Cancer Research Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas Scott M. Haake, Jamie D. Weyandt, and W. Kimryn Rathmell Abstract The renal cell carcinomas (RCC), clear cell, papillary, and mutations in chromatin modifier genes. Importantly, the pap- chromophobe, have recently undergone an unmatched geno- illary RCC classification encompasses a heterogeneous group mic characterization by The Cancer Genome Atlas. This anal- of diseases, each with highly distinct genetic and molecular ysis has revealed new insights into each of these malignancies features. In conclusion, this review summarizes RCCs that and underscores the unique biology of clear cell, papillary, and represent a diverse set of malignancies, each with novel bio- chromophobe RCC. Themes that have emerged include dis- logic programs that define new paradigms for cancer biology. tinct mechanisms of metabolic dysregulation and common Mol Cancer Res; 14(7); 589–98. Ó2016 AACR. Introduction ullary carcinoma and translocation carcinoma. It is anticipated that a revised World Health Organization (WHO) pathologic Cancers of the kidney have long fascinated physicians with classification recognizing even more rare and largely low-risk their highly divergent phenotypes and patterns of behavior (1). entities, such as clear cell tubulopapillary RCC and multi- Kidney tumors are conventionally grouped based upon their locular cystic RCC, will be published in 2016
    [Show full text]
  • C. Elegans Whole Genome Sequencing Reveals Mutational Signatures Related to Carcinogens and DNA Repair Deficiency
    Downloaded from genome.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press C. elegans whole genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency Authors: Bettina Meier * (1); Susanna L Cooke * (2); Joerg Weiss (1); Aymeric P Bailly (1,3); Ludmil B Alexandrov (2); John Marshall (2); Keiran Raine (2); Mark Maddison (2); Elizabeth Anderson (2); Michael R Stratton (2); Anton Gartner * (1); Peter J Campbell * (2,4,5). * These authors contributed equally to this project. Institutions: (1) Centre for Gene Regulation and Expression, University of Dundee, Dundee, UK. (2) Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK. (3) CRBM/CNRS UMR5237, University of Montpellier, Montpellier, France. (4) Department of Haematology, University of Cambridge, Cambridge, UK. (5) Department of Haematology, Addenbrooke’s Hospital, Cambridge, UK. Address for correspondence: Dr Peter J Campbell, Dr Anton Gartner, Cancer Genome Project, Centre for Gene Regulation and Expression, Wellcome Trust Sanger Institute, The University of Dundee, Hinxton CB10 1SA, Dow Street, Cambridgeshire, Dundee DD1 5EH UK. UK. Tel: +44 (0) 1223 494745 Phone: +44 (0) 1382 385809 Fax: +44 (0) 1223 494809 E-mail: a.gartner@dundee.ac.uk E-mail: pc8@sanger.ac.uk Running title: mutation profiling in C. elegans Keywords: mutation pattern, genetic and environmental factors, C. elegans, cisplatin, aflatoxin B1, whole-genome sequencing. Downloaded from genome.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Mutation is associated with developmental and hereditary disorders, ageing and cancer. While we understand some mutational processes operative in human disease, most remain mysterious.
    [Show full text]
  • Abstracts In
    ECCB 2014 Accepted Posters with Abstracts G: Bioinformatics of health and disease G01: Emile Rugamika Chimusa, Jacquiline Wangui Mugo and Nicola Mulder. Leveraging ancestry along the genome of admixed individuals to resolve missing heritability in disease scoring statistics Abstract: Human genetics has been haunted by the mystery of “missing heritability” of common traits. Although studies have discovered several variants associated with common diseases and traits, these variants typically appear to explain only a minority of the heritability. Resolving missing heritability, the difference between phenotypic variance explained by associated SNPs and estimates of narrow-sense heritability (h2), will inform strategies for disease mapping and prediction of complex traits. Among biased estimates of h2 due to epistatic interactions and rare variants not captured by genotyping arrays have been cited to be the most can be the most explanations for missing heritability. Here, we present an approach for estimating heritability of traits based on sharing local ancestry segments between pairs of unrelated individuals in an admixed population. From simulation data and real data, we demonstrated that our approach outperformed current approaches for estimating heritability of traits and holds values in admixture mapping for deconvoluting genes underlying ethnic differences in complex diseases risk. G02: Sylvain Mareschal, Pierre-Julien Viailly, Philippe Bertrand, Fabienne Desmots-Loyer, Elodie Bohers, Catherine Maingonnat, Karen Leroy, Thierry Fest and Fabrice Jardin. Next- Generation Sequencing applied to tailor targeted therapies in lymphoma: the RELYSE project Abstract: Non-Hodgkin Lymphomas (NHL) are lymphoid cell malignancies accounting for about 4% of all cancers, with an incidence rate of 12 cases per 100,000 and per year in Europe.
    [Show full text]
  • Deep Learning-Based Gene Selection in Comprehensive Gene Analysis In
    www.nature.com/scientificreports OPEN Deep learning‑based gene selection in comprehensive gene analysis in pancreatic cancer Yasukuni Mori1*, Hajime Yokota2, Isamu Hoshino3, Yosuke Iwatate4, Kohei Wakamatsu5, Takashi Uno2 & Hiroki Suyari1 The selection of genes that are important for obtaining gene expression data is challenging. Here, we developed a deep learning‑based feature selection method suitable for gene selection. Our novel deep learning model includes an additional feature‑selection layer. After model training, the units in this layer with high weights correspond to the genes that worked efectively in the processing of the networks. Cancer tissue samples and adjacent normal pancreatic tissue samples were collected from 13 patients with pancreatic ductal adenocarcinoma during surgery and subsequently frozen. After processing, gene expression data were extracted from the specimens using RNA sequencing. Task 1 for the model training was to discriminate between cancerous and normal pancreatic tissue in six patients. Task 2 was to discriminate between patients with pancreatic cancer (n = 13) who survived for more than one year after surgery. The most frequently selected genes were ACACB, ADAMTS6, NCAM1, and CADPS in Task 1, and CD1D, PLA2G16, DACH1, and SOWAHA in Task 2. According to The Cancer Genome Atlas dataset, these genes are all prognostic factors for pancreatic cancer. Thus, the feasibility of using our deep learning‑based method for the selection of genes associated with pancreatic cancer development and prognosis was confrmed. Deep learning techniques have produced impressive results in many felds, including image classifcation, image generation, automated driving, and even board gameplay 1–6. A great deal of research is now being conducted to apply the superior inference performance of deep learning to the feld of medicine 7,8.
    [Show full text]
  • Association of RYR2 Mutation with Tumor Mutation Burden, Prognosis
    ORIGINAL RESEARCH published: 17 May 2021 doi: 10.3389/fgene.2021.669694 Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma Zaoqu Liu 1,2,3†, Long Liu 4†, Dechao Jiao 1, Chunguang Guo 5, Libo Wang 4, Zhaonan Li 1, Zhenqiang Sun 6, Yanan Zhao 1,2,3* and Xinwei Han 1,2,3* 1 Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 2 Interventional Institute of Zhengzhou University, Zhengzhou, China, 3 Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China, 4 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Edited by: 5 Valerio Costa, Zhengzhou University, Zhengzhou, China, Department of Endovascular Surgery, The First Affiliated Hospital of Zhengzhou 6 Consiglio Nazionale delle Ricerche University, Zhengzhou, China, Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, (CNR), Italy Zhengzhou, China Reviewed by: Umberto Malapelle, Background: Esophageal adenocarcinoma (EAC) remains a leading cause of cancer- University of Naples Federico II, Italy related deaths worldwide and demonstrates a predominant rising incidence in Western Valentina Silvestri, Sapienza University of Rome, Italy countries. Recently, immunotherapy has dramatically changed the landscape of treatment *Correspondence: for many advanced cancers, with the benefit in EAC thus far been limited to a small fraction Yanan Zhao of patients. yananzhao996@163.com Xinwei Han Methods: Using somatic mutation data of The Cancer Genome Atlas (TCGA) and the fcchanxw@zzu.edu.cn International Cancer Genome Consortium, we delineated the somatic mutation landscape † These authors have contributed of EAC patients from US and England.
    [Show full text]
  • Oncogenomic Portals for the Visualization and Analysis of Genome-Wide Cancer Data
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 1 Oncogenomic portals for the visualization and analysis of genome-wide cancer data Katarzyna Klonowska1, Karol Czubak1, Marzena Wojciechowska1, Luiza Handschuh1,2, Agnieszka Zmienko1,3, Marek Figlerowicz1,3, Hanna Dams- Kozlowska4,5 and Piotr Kozlowski1 1 European Centre for Bioinformatics and Genomics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland 2 Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland 3 Institute of Computing Sciences, Poznan University of Technology, Poznan, Poland 4 Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland 5 Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland Correspondence to: Piotr Kozlowski, email: kozlowp@yahoo.com Keywords: cBioPortal, COSMIC, IntOGen, PPISURV/MIRUMIR, Tumorscape Received: June 18, 2015 Accepted: September 28, 2015 Published: October 15, 2015 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Somatically acquired genomic alterations that drive oncogenic cellular processes are of great scientific and clinical interest. Since the initiation of large-scale cancer genomic projects (e.g., the Cancer Genome Project, The Cancer Genome Atlas, and the International Cancer Genome Consortium cancer genome projects), a number of web-based portals have been created to facilitate access to multidimensional oncogenomic data and assist with the interpretation of the data. The portals provide the visualization of small-size mutations, copy number variations, methylation, and gene/protein expression data that can be correlated with the available clinical, epidemiological, and molecular features.
    [Show full text]
  • Human Genetics: International Projects and Personalized Medicine
    Drug Metabol Pers Ther 2016; 31(1): 3–8 Mini Review Maria Apellaniz-Ruiza, Cristina Gallegoa, Sara Ruiz-Pintoa, Angel Carracedo and Cristina Rodríguez-Antona* Human genetics: international projects and personalized medicine DOI 10.1515/dmpt-2015-0032 Received August 31, 2015; accepted October 19, 2015; previously Introduction published online November 18, 2015 Genetic variation databases describe naturally occur- Abstract: In this article, we present the progress driven ring genetic differences among individuals of the same by the recent technological advances and new revolu- species. This variation, accounting for 0.1% of our DNA tionary massive sequencing technologies in the field of [1], permits the flexibility and survival of a population human genetics. We discuss this knowledge in relation in the face of changing environmental circumstances, with drug response prediction, from the germline genetic but it also influences how people differ in their risk of variation compiled in the 1000 Genomes Project or in the disease or their response to drugs. It is well known that Genotype-Tissue Expression project, to the phenome- variability in response to drug therapy is the rule rather genome archives, the international cancer projects, such than the exception for most drugs, and these differences as The Cancer Genome Atlas or the International Cancer are among the major challenges in current clinical prac- Genome Consortium, and the epigenetic variation and its tice, drug development, and drug regulation [2, 3]. Thus, influence in gene expression, including the regulation of rather than accepting the “one drug fits all” approach, drug metabolism. This review is based on the lectures pre- researchers envision that drugs need to be tailored to fit sented by the speakers of the Symposium “Human Genet- the profile of each individual patient.
    [Show full text]
  • Metastatic Adrenocortical Carcinoma Displays Higher Mutation Rate and Tumor Heterogeneity Than Primary Tumors
    ARTICLE DOI: 10.1038/s41467-018-06366-z OPEN Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors Sudheer Kumar Gara1, Justin Lack2, Lisa Zhang1, Emerson Harris1, Margaret Cam2 & Electron Kebebew1,3 Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is 1234567890():,; unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs. 1 Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2 Center for Cancer Research, Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 3 Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. Correspondence and requests for materials should be addressed to E.K. (email: kebebew@stanford.edu) NATURE COMMUNICATIONS | (2018) 9:4172 | DOI: 10.1038/s41467-018-06366-z | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06366-z drenocortical carcinoma (ACC) is a rare malignancy with types including primary ACC from the TCGA to understand our A0.7–2 cases per million per year1,2.
    [Show full text]
  • The Challenge of Developing Cancer Biomarkers
    Downloaded from genome.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Perspective Translational genomics: The challenge of developing cancer biomarkers James D. Brooks1 Department of Urology, Stanford University, Stanford, California 94305, USA Early detection and definitive treatment of cancer have been shown to decrease death and suffering in epidemiologic and intervention studies. Application of genomic approaches to many malignancies has produced thousands of candidate biomarkers for detection and prognostication, yet very few have become established in clinical practice. Fundamental issues related to tumor heterogeneity, cancer progression, natural history, and biomarker performance have provided challenges to biomarker development. Technical issues in biomarker assay detection limits, specificity, clinical de- ployment, and regulation have also slowed progress. The recent emergence of biomarkers and molecular imaging strategies for treatment selection and monitoring demonstrates the promise of cancer biomarkers. Organized efforts by interdisciplinary teams will spur progress in cancer diagnostics. Since the war on cancer was declared in 1972, cancer death rates, and many have been tested on clinical samples and show some after rising for several decades, have begun to slowly decline (Siegel utility. There the story usually stops (Ludwig and Weinstein 2005; et al. 2011). This drop can be attributed to preventive efforts (e.g., Ioannidis and Panagiotou 2011). In fact, the number of biomarkers smoking cessation), improved treatments for advanced disease, approved by the FDA each year for clinical use is in the single digits. and early detection and treatment of localized cancers. Future This drop-off rate shows that the development of biomarkers is progress in prevention and treatment of advanced disease requires every bit as difficult as the development and approval of a new drug.
    [Show full text]
  • Strategic Plan 2011-2016
    Strategic Plan 2011-2016 Wellcome Trust Sanger Institute Strategic Plan 2011-2016 Mission The Wellcome Trust Sanger Institute uses genome sequences to advance understanding of the biology of humans and pathogens in order to improve human health. -i- Wellcome Trust Sanger Institute Strategic Plan 2011-2016 - ii - Wellcome Trust Sanger Institute Strategic Plan 2011-2016 CONTENTS Foreword ....................................................................................................................................1 Overview .....................................................................................................................................2 1. History and philosophy ............................................................................................................ 5 2. Organisation of the science ..................................................................................................... 5 3. Developments in the scientific portfolio ................................................................................... 7 4. Summary of the Scientific Programmes 2011 – 2016 .............................................................. 8 4.1 Cancer Genetics and Genomics ................................................................................ 8 4.2 Human Genetics ...................................................................................................... 10 4.3 Pathogen Variation .................................................................................................. 13 4.4 Malaria
    [Show full text]
  • 2019 AACR TET TCGA Poster FINAL
    Comprehensive analysis of thymic epithelial tumors using an integrated bioinformatics platform reveals novel biological characteristics Milan Radovich1, Jeffrey P. Solzak1, J Ireland2, Wade Webster2, Jesse Paquette2 1Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA; 2Tag.bio, San Francisco, CA, USA Background Methods Results Source data: Thymoma TCGA dataset cBioPortal (http://www.cbioportal.orG/study?id=thym_tcGa) 1. Differential expression identifies high tumoral overexpression of muscle autoantigens in patients with Myasthenia Gravis • Thymic epithelial tumors (TETs) are rare maliGnancies Statistical methods with ~500 cases diaGnosed in the US per year Statistical analyses for results 1A, 1B, 2 and 3A were performed usinG TaG.bio protocol apps. Upstream Predicted https://omics.taG.bio/fc-thym/custom/confiG A B Gene P-value Fold-change C Transcriptional Activation • AmonG TETs, thymoma is the most predominant, Analysis 1 - Differential expression for patients with Myasthenia Gravis The expression distribution for each Gene was compared between two cohorts: patients with Myasthenia PPARGC1A Regulator State Z-score P-value -4 characterized by a unique association with myasthenia Gravis (focus cohort) and patients without Myasthenia Gravis (comparison cohort). PPARGC1A <1x10 5.81 PPARGC1A Activated 3.796 0.00347 Statistical test: Mann-Whitney u-test. Raw p-values and false discovery rate estimates (q-values) were Gravis, followed by thymic carcinoma which is less -4 SOX1 Activated 2.887 0.0322 generated. NEFM NEFM <1x10 27.66 common but more clinically aGGressive. Analysis 2 - Differential expression for patients with metastatic Thymoma SOX2 Activated 2.581 0.0178 -3 The expression distribution for each Gene was compared between two cohorts: patients with Masaoka- NEFL <1x10 35.87 AIRE Activated 2.433 0.24 • The Cancer Genome Atlas (TCGA) recently published a KoGa staGe IVa or IVb (focus cohort), and patients with other staGes of the disease (comparison cohort).
    [Show full text]
  • Une Version Provisoire Initiale De Ce Livre Blanc a Été Préparée Pour La Réunion Du 28 Janvier. Elle a Été Révisée De M
    Une version provisoire initiale de ce Livre blanc a été préparée pour la réunion du 28 janvier. Elle a été révisée de manière substantielle depuis cette date, suite à des discussions pendant et après la réunion. La liste des contributeurs et des participants se trouve à la fin de ce document. 1 Sommaire Introduction................................................................................................................3 Chapitre 1. Présentation du contexte ......................................................................4 Pourquoi maintenant ? ..........................................................................................5 Impact potentiel sur la santé humaine.................................................................7 Encadré 1. Répondre aux besoins de l’écosystème biomédical dans son ensemble .............................................................................................................8 Recruter des parties prenantes ............................................................................9 Recruter des parties prenantes : attitudes du public envers le partage des données................................................................................................................9 Recruter des parties prenantes : prestataires de soins de santé .......................11 Recruter des parties prenantes : secteur industriel............................................12 Recruter des parties prenantes : définition de normes.......................................12 Une voie à suivre..................................................................................................13
    [Show full text]